UAB Comprehensive Cancer Center Magazine Winter 2018 2018 Volume XXXIII Number 3 - Page 20

research update Saleh: “We were using recombinant DNA technology. We knew the gene for the Fc portion of the antibody [which interacts with a patient’s immune system], so we took the gene for the human Fc portion, and the gene for the mouse Fab portion, which binds to the target. It was 80 percent human and 20 percent mouse: that’s a chimeric antibody. “The kinetics for the chimeric antibody was multiple days. It wasn’t 21 days, which is the half-life of human immunoglobulin, but it was much longer than mouse antibodies. About 5-7 days, as opposed to 5-6 hours.” “The first person treated in the first clinical trial of Adcetris was one of my patients here at UAB. We went through all the steps of those studies, and it was approved by the FDA for Hodgkin’s lymphoma a few years ago. It has dramatically improved treatment.” Andres Forero, M.D. 18 U A B LoBuglio: “We did the first trial in a human and it worked well. Our conclusion was that these genetically engineered antibodies w ɔ)ݡЁѼ͕ȁ今t)MՉ͕ՕЁՑ́ЁUȁѡɅѥ)̰Ёѡɕ͔݅́ȸ)1 ՝胊q]ѕЁѡЁѡѥ)ɽ䁹ѼѕɅЁݥѠɕѽȁ)ձѡЁ݅́٥хѼѡ٥مѡ)յȸ%ЁձeЁЁхPЁѼ)ͽѡѡЁ݅́ɥѥeԁѼ)ձ́ѡəѡյȁ́ѡ)ձѕѼѡյȸ%Ё݅)ȁѡЁ́ѥ́ձ)锁Ѽյȁͥѕ̰ԁɅ)ѡݡݔԁձѕЁ݅)ѥѡɔ%ЁЁ݅ͻeЁѥѼ)ѡյȸ]Ѽ٥хձ)ѡəѡ+qIᅸ݅́ѡ՝́ѡЁѡ)и%ЁɕѕݥѠ mɅ)ɽѕѡѕɅt)Ёѡ)хЁѕəɕݥѠȁ́)ѡѡѕЁՉ̻t)Iᅸٕ݅́䁄䁍% )Aɵѥ̰͕M ɹ)1 ՝٥ͽɽݥѠ% ) <4@H 8L$X) 8 H) 8PH)1 ՝胊q]եєɕхѥ)ѡ]ݥѠձ䁥ѡ)ɅѥѡɅ䰁չ䰁ѕɹ)Q́ݽɬѡЁɔՅ)ѡ͔ݔݕɔѼ)յ̸Qȁɕͽȁѥ)ѡ͔ɥ́݅́ѡѥ͔ѡЁݔ)́ͥɥ̸)]ѡѡɕȁȁ啅̰ݔձ͕)ݡѕٕȁѹ́ݔ݅ѕɽѡ)ɥͥѡѥ)%ӊéٕѵЁѼ)՝5́ѼٔѼյ̰ͼ)ɔȁݡѡ́ݕt+q=ݽɭݥѠ́)ѥ䁕ɕѥ䁑ɕѕЁ)ɵɽѠѽȁɕѽȸQЁɥ)͡ݕѡЁѥ́́Ʌѥձ)͡ɥյ̸]Չ͡ѡЁѡ)ݕЁٽхɥ́ȁɽم)ѡ՜ݡɉกQӊéѥ)ѡɥɕѵ́ȁ)Ȱѡٽхɥ݅́ɔݥѠ)ȁȁɅѥѡɅ䁅́ѡɥ)ٕѥѽȸ+q]ͼݡ͕ɥ́ѥɥ)ݥѠѽ᥹́хѼѡѥͼѡЁ)ٕɕ՜ȁѽ᥌ձt)M胊q%ӊéɽ͔eԁٔ)ѥ́ѼѡɅ䰁ͼѡ)ѥ䁅х́Ѽѡյȁѡ)ѡɅ͹́eԁٔѼٔ)ȁݕѡѥ䁅ѡ)ѡɅ屽ѡ́)݅́ͽЁ͡丁=ȁЁȁݥѠ)ѡЁٽٕչ՝єݡɔѡ)ѥٕ݅́ѕЁЁѡȁ݅)ٕ͡䰁ѡѡɅݽձ)Qɔ݅́եєЁѽ᥍丁]ݕɔ)ѡЁѼչ՝єѡɅ)յ́ɔЁUЁЁ݅́ѥٔ)]͡ݕѡչɕ͔Ёͼѡ)ѡȁ݅́ݕѡѡɅ݅)t